653 related articles for article (PubMed ID: 17367311)
1. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
4. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
5. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
Weinberg AJ; Zappe DH; Ramadugu R; Weinberg MS
J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
[TBL] [Abstract][Full Text] [Related]
10. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
12. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
[TBL] [Abstract][Full Text] [Related]
15. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
17. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
19. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Inoue A; Babazono T; Iwamoto Y
Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
